Prosafe SE: Operational Update - April 2024
Fleet utilization for Q1 2024 was 56 percent.
Safe Notos and Safe Zephyrus had utilization of 100 percent in Q1 2024 while Safe Eurus had utilization of 95 percent.
Safe Concordia had utilization of 100 percent in Q1 2024 and received 95% day rate until 01 February due to crane repair.
Safe Caledonia is laid up at Scapa Flow in the UK pending future work.
Safe Boreas and Safe Scandinavia are laid up in Norway pending future work.
Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to https://www.prosafe.com
Stavanger, 19 April 2024
Prosafe SE
For further information, please contact:
Terje Askvig, CEO
Phone: +47 952 03 886
Reese McNeel, CFO
Phone: +47 415 08 186
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 20242.5.2024 07:30:49 CEST | Press release
Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales in North America Operations increased by 34% in Danish kroner (35% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 8% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 25% in Danish kroner to DKK 61.0 billion (27% at CER), mainly driven by GLP-1 diabetes sales growth of 30% in Danish kroner (32% at CER) and Obesity care growing by 41% in Danish kroner to DKK 11.0 billion (42% at CER). Rare disease sales decreased by 4% measured in Danish kroner (3% at CER).In the first quarter of 2024, Novo Nordisk successfully completed the FLOW kidney outcomes trial with semaglutide 1.0 mg. Further, Wegovy® was approved in the US for cardiovasc
Promising start to the year with continued business improvements2.5.2024 07:30:28 CEST | Press release
Company Announcement Copenhagen, 2 May 2024 No. 19/2024 Trading update for 1 January – 31 March 2024 Promising start to the year with continued business improvements Highlights Organic growth was 6.0% in Q1 2024 (Q1 2023: 12.0%). Total revenue for the quarter amounted to DKK 20.1 billion (Q1 2023: DKK 19.3 billion).The organic growth development was mainly driven by successful implementation of price increases to offset wage increases and general cost inflation and volume growth.The operating margin developed in line with plan. This was mainly driven by continued operational improvements and efficiencies. Costs related to mobilisation of contracts won in 2023 have been incurred in the quarter. During the first months of the year, ISS has secured several smaller and mid-sized local IFS contract wins and extended contracts with Nordea and a global bank.In the beginning of April 2024, the divestment of ISS France was completed. Financial leverage remains broadly unchanged following the di
Ipsen appoints Keira Driansky as EVP, President of North America2.5.2024 07:30:00 CEST | Press release
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership Team (ELT) and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “We are thrilled to welcome Keira to Ipsen as our new President of North America as she brings extensive experience in the life sciences industry and a proven track record of leadership to our team,” said David Loew, CEO Ipsen. “As we continue to navigate the complexities of the pharmaceutical landscape, Keira’s strategic vision will be instrumental in guiding our company toward a future of bringing groundbreaking medicines and enhanced outcomes to patients.” Keira will be joining Ipsen from AstraZeneca, where she spent the last 13 years leading teams across the US, Europe and global functions. Most recently Keira served as Country Presid
Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: results of Simplified Squeeze-Out Acceptance Period of TPG on Intervest2.5.2024 07:30:00 CEST | Press release
Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the results of Simplified Squeeze-Out Acceptance Period of TPG on Intervest. Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de resultaten aan van de Aanvaardingsperiode van het vereenvoudigd uitkoopbod van TPG op Intervest. Chère Madame, Cher Monsieur, Veuillez trouver ci-dessous les liens vers le récent communiqué de presse d’Intervest Offices & Warehouses concernant les résultats de la période d'acceptation de l’offre de reprise simplifiée de TPG sur Intervest. Attachments EN_Intervest results squeezeout_finNL_Intervest results squeezeout_finFR_Intervest results squeezeout_fin
Pandora delivers 18% organic growth in Q1 – raises 2024 revenue guidance2.5.2024 07:30:00 CEST | Press release
Financial highlights The second phase of Pandora’s Phoenix strategy is off to a strong start. Increased investments are elevating brand desirability and showcasing Pandora’s position as a full jewellery brand.Continued momentum, helped by the early restaging of the brand, drives strong Q1 2024 trading; organic growth ends at 18% with Like-for-like (LFL) growth of 11% and network expansion of 5%.In absolute terms, revenue increased by DKK 1.0 billion compared to Q1 2023.LFL growth in key European markets of 9%, US remaining solid at 9% and Rest of Pandora at 18%.The gross margin reached a new record-high of 79.4%, +190bp vs Q1 2023, supported by channel mix, pricing and efficiencies, as well as some tailwind from silver prices and foreign exchange rates.The Q1 2024 EBIT margin landed at 22.0%, +50bp ahead of last year, reflecting the strong growth which more than offset the planned step-up in marketing investments as part of the restaging of the brand. Leverage remains low at a NIBD/EBI